A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Paricalcitol (Primary) ; Pembrolizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Carcinoma; Pancreatic cancer
- Focus Adverse reactions
- 21 Feb 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Feb 2020.
- 21 Feb 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Mar 2020.